An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
News|Videos|June 12, 2025 (Updated: September 10, 2025)
Tirabrutinib for the Treatment of Relapsed or Refractory Primary Central Nervous System Lymphoma: Efficacy and Safety From the Phase II PROSPECT Study
Author(s)Lakshmi Nayak, MD
Dr. Lakshmi Nayak presents results from the Phase II PROSPECT study, demonstrating that tirabrutinib monotherapy yields a 66.7% overall response rate and a manageable safety profile in patients with relapsed or refractory primary central nervous system lymphoma, supporting its potential as an effective treatment option in this challenging population.
Advertisement
Advertisement
Related to this article
Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
4
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
5